We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Refinitiv and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from our Featured Companies page.
Scancell
FY24: Cash to deliver on key clinical catalystsAvacta
ESMO 24: compelling data for AVA6000 and pre|CISIONArecor Therapeutics
EASD 2024: Positive Phase I for AT278 in Type II diabetesFutura Medical
Earlier US Eroxon launch brings forward profitabilityFutura Medical
Maiden H1 profit; FY profit expected with Q3 US launchHUTCHMED
Continued H124 execution; well on-track to meet targetsFutura Medical
Haleon confirms US Eroxon launch by end-2024Arecor Therapeutics
Funding growth; diabetes still the key value driverHUTCHMED
R&D day highlights prospects for key late-stage productsRedx Pharma
Focus remains firmly on fibrosis and related diseases